Daniel Wegener

Dr. Daniel Wegener

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
JLJoerg Latus
Joerg Latus
Matthias SchwabMatthias Schwab
Matthias Schwab
ETEvelina Tacconelli
Evelina Tacconelli
FPFriedrich-Michael Pieper
Friedrich-Michael Pieper
DWDaniel Wegener
Daniel Wegener
NBNiko Braun
Niko Braun
Human infection with Puumala virus (PUUV), the most common hantavirus in Central Europe, causes nephropathia epidemica (NE), a disease characterized by acute kidney injury and thrombocytopenia. To determine the clinical phenotype of hantavirus-infected patients and their long-term outcome and humoral immunity to PUUV, we conducted a cross-sectional prospective survey of 456 patients in Germany with clinically and serologically confirmed hantavirus-associated NE during 2001–2012. Prominent clinical findings during acute NE were fever and back/limb pain, and 88% of the patients had acute kidney injury. At follow-up (7–35 mo), all patients had detectable hantavirus-specific IgG; 8.5% had persistent IgM; 25% had hematuria; 23% had hypertension (new diagnosis for 67%); and 7% had proteinuria. NE-associated hypertension and proteinuria do not appear to have long-term consequences, but NE-associated hematuria may. All patients in this study had hantavirus-specific IgG up to years after the infection.

13 October 2014 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
JLJoerg Latus
Joerg Latus
Matthias SchwabMatthias Schwab
Matthias Schwab
ETEvelina Tacconelli
Evelina Tacconelli
FPFriedrich-Michael Pieper
Friedrich-Michael Pieper
DWDaniel Wegener
Daniel Wegener
NBNiko Braun
Niko Braun
Puumala virus (PUUV) is the most common species of hantavirus in Central Europe. Nephropathia epidemica (NE), caused by PUUV, is characterized by acute kidney injury (AKI) and thrombocytopenia. The major goals of this study were to provide a clear clinical phenotyping of AKI in patients with NE and to develop an easy prediction rule to identify patients, who are at lower risk to develop severe AKI. A cross-sectional prospective survey of 456 adult patients with serologically confirmed NE was performed. Data were collected from medical records and prospectively at follow-up visit. Severe AKI was defined by standard criteria according to the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) classification. Fuller statistical models were developed and validated to estimate the probability for severe AKI. During acute NE, 88% of the patients had AKI according to the RILFE criteria during acute NE. A risk index score for severe AKI was derived by using three independent risk factors in patients with normal kidney function at time of diagnosis: thrombocytopenia [two points; odds ratios (OR): 3.77; 95% confidence intervals (CI): 1.82, 8.03], elevated C-reactive protein levels (one point; OR: 3.02; 95% CI: 1.42, 6.58) and proteinuria (one point; OR: 3.92; 95% CI: 1.33, 13.35). On the basis of a point score of one or two, the probability of severe AKI was 0.18 and 0.28 with an area under the curve of 0.71. This clinical prediction rule provides a novel and diagnostically accurate strategy for the potential prevention and improved management of kidney complications in patients with NE and, ultimately, for a possible decrease in unnecessary hospitalization in a high number of patients.

8 March 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JSJohannes Schwenck
Johannes Schwenck
SOSusann-Cathrin Olthof
Susann-Cathrin Olthof
CPChristina Pfannenberg
Christina Pfannenberg
Gerald ReischlGerald Reischl
Gerald Reischl
DWDaniel Wegener
Daniel Wegener
AMArndt-Christian Müller
Arndt-Christian Müller
Biochemical recurrence (BCR) after prostate cancer surgery is very common, even after additional salvage radiotherapy (SRT). This might be explained by target miss. Improved diagnostic accuracy provided by PET could potentially circumvent this therapeutic gap. Therefore, we evaluated consecutive 68Ga-PSMA-, 11C-choline PET/CT and standard CT imaging in the same patient with regard to TNM-stage migration and accordingly adapted curative radiotherapy (RT) options including ablative treatment of oligometastases (n≤5). Cost efficacy of PET- versus CT-based treatment is also calculated. The prospective register database (064/2013BO1) was retrospectively searched for patients fulfilling the following inclusion criteria: 1. BCR after radical prostatectomy (pT2-4 pN0-1 cM0, postoperative RT allowed). 2. 11C-choline, 68Ga-PSMA-PET/CT and diagnostic CT performed within the same day. 3. Available clinical data. Ten treatment routines were defined according to current practice. Furthermore, intention to treat and treatment-related costs depending on stage shift of TNM-staging after imaging were analyzed. Eighty-three patients were eligible (median PSA-level 1.9 ng/ml). Both PET-examinations led to concordant results in 72% of patients, while concordance of TNM-staging between 68Ga-PSMA-PET and diagnostic CT was only 36%. Incorrect staging would lead to “wrong” treatment and therefore to additional costs. A 68Ga-PSMA-PET would be cost-effective if additional costs do not exceed 3,843 € (vs. CT). The number needed to image (NNI) was 2 (for CT) and 4 (for 11C-choline-PET) to avoid one incorrect treatment. In addition, 68Ga-PSMA-PET-staging enabled new curative options in half of the patients with previous RT who otherwise receive palliative ADT. 68Ga-PSMA PET/CT is cost-effective with regard to avoided incorrect treatment for all patients. It enabled new curative options for patients with previous RT who are usually treated palliatively. Therefore, PSMA-PET/CT staging should become standard for BCR after surgery±RT.

26 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HAHaidara Almansour
Haidara Almansour
Saif AfatSaif Afat
Saif Afat
VFVictor Fritz
Victor Fritz
FSFritz Schick
Fritz Schick
MNMarcel Nachbar
Marcel Nachbar
DWDaniel Wegener
Daniel Wegener
The objective of this study is to conduct a qualitative and a quantitative image quality and lesion evaluation in patients undergoing MR-guided radiation therapy (MRgRT) for prostate cancer on a hybrid magnetic resonance imaging and linear accelerator system (MR-Linac or MRL) at 1.5 Tesla. This prospective study was approved by the institutional review board. A total of 13 consecutive patients with biopsy-confirmed prostate cancer and an indication for MRgRT were included. Prior to radiation therapy, each patient underwent an MR-examination on an MRL and on a standard MRI scanner at 3 Tesla (MRI3T). Three readers (two radiologists and a radiation oncologist) conducted an independent qualitative and quantitative analysis of T2-weighted (T2w) and diffusion-weighted images (DWI). Qualitative outcome measures were as follows: zonal anatomy, capsule demarcation, resolution, visibility of the seminal vesicles, geometric distortion, artifacts, overall image quality, lesion conspicuity, and diagnostic confidence. All ratings were performed on an ordinal 4-point Likert scale. Lesion conspicuity and diagnostic confidence were firstly analyzed only on MRL. Afterwards, these outcome parameters were analyzed in consensus with the MRI3T. Quantitative outcome measures were as follows: anteroposterior and right left diameter of the prostate, lesion size, PI-RADS score (Prostate Imaging—Reporting and Data System) and apparent diffusion coefficient (ADC) of the lesions. Intergroup comparisons were computed using the Wilcoxon-sign rank test and t tests. A post-hoc regression analysis was computed for lesion evaluation. Finally, inter-/intra-reader agreement was analyzed using the Fleiss kappa and intraclass correlation coefficient. For T2w images, the MRL showed good results across all quality criteria (median 3 and 4). Furthermore, there were no significant differences between MRL and MRI3T regarding capsule demarcation or geometric distortion. For the DWI, the MRL performed significantly less than MRI3T across most image quality criteria with a median ranging between 2 and 3. However, there were no significant differences between MRL and MRI3T regarding geometric distortion. In terms of lesion conspicuity and diagnostic confidence, inter-reader agreement was fair for MRL alone (Kappa = 0.42) and good for MRL in consensus with MRI3T (Kappa = 0.708). Thus, lesion conspicuity and diagnostic confidence could be significantly improved when reading MRL images in consensus with MRI3T (Odds ratio: 9- to 11-fold for the T2w images and 5- to 8–fold for the DWI) (p < 0.001). For measures of lesion size, anterior-posterior and right-left prostate diameter, inter-reader and intersequence agreement were excellent (ICC > 0.90) and there were no significant differences between MRL and MRI3T among all three readers. In terms of Prostate Imaging Reporting and Data System (PIRADS) scoring, no significant differences were observed between MRL and MRI3T. Finally, there was a significant positive linear relationship between lesion ADC measurements (r = 0.76, p < 0.01) between the ADC values measured on both systems. In conclusion, image quality for T2w was comparable and diagnostic even without administration of spasmolytic- or contrast agents, while DWI images did not reach diagnostic level and need to be optimized for further exploitation in the setting of MRgRT. Diagnostic confidence and lesion conspicuity were significantly improved by reading MRL in consensus with MRI3T which would be advisable for a safe planning and treatment workflow. Finally, ADC measurements of lesions on both systems were comparable indicating that, lesion ADC as measured on the MRL could be used as a biomarker for evaluation of treatment response, similar to examinations using MRI3T.

1 November 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CGCihan Gani
Cihan Gani
MRMonica Lo Russo
Monica Lo Russo
SBSimon Boeke
Simon Boeke
DWDaniel Wegener
Daniel Wegener
SGSergios Gatidis
Sergios Gatidis
MNMarcel Nachbar
Marcel Nachbar

9 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DWDaniel Wegener
Daniel Wegener
ATAlexandra Thome
Alexandra Thome
FPFrank Paulsen
Frank Paulsen
CGCihan Gani
Cihan Gani
JBJessica Boldt
Jessica Boldt
SBSimon Boeke
Simon Boeke
Introduction: Novel MRI-linear accelerator hybrids (MR-Linacs, MRL) promise an optimization of radiotherapy (RT) through daily MRI imaging with enhanced soft tissue contrast and plan adaptation on the anatomy of the day. These features might potentially improve salvage RT of prostate cancer (SRT), where the clinical target volume is confined by the mobile organs at risk (OAR) rectum and bladder. So far, no data exist about the feasibility of the MRL technology for SRT. In this study, we prospectively examined patients treated with SRT on a 1.5 T MRL and report on workflow, feasibility and acute toxicity. Patients and Methods: Sixteen patients were prospectively enrolled within the MRL-01 study (NCT: NCT04172753). All patients were staged and had an indication for SRT after radical prostatectomy according to national guidelines. RT consisted of 66 Gy in 33 fractions or 66.5/70 Gy in 35 fractions in case of a defined high-risk region. On the 1.5 T MRL, daily plan adaption was performed using one of two workflows: adapt to shape (ATS, using contour adaptation and replanning) or adapt to position (ATP, rigid replanning onto the online anatomy with virtual couch shift). Duration of treatment steps, choice of workflow and treatment failure were recorded for each fraction of each patient. Patient-reported questionnaires about patient comfort were evaluated as well as extensive reporting of acute toxicity (patient reported and clinician scored). Results: A total of 524/554 (94.6%) of fractions were successfully treated on the MRL. No patient-sided treatment failures occurred. In total, ATP was chosen in 45.7% and ATS in 54.3% of fractions. In eight cases, ATP was performed on top of the initial ATS workflow. Mean (range) duration of all fractions (on-table time until end of treatment) was 25.1 (17.6–44.8) minutes. Mean duration of the ATP workflow was 20.60 (17.6–25.2) minutes and of the ATS workflow 31.3 (28.2–34.1) minutes. Patient-reported treatment experience questionnaires revealed high rates of tolerability of the treatment procedure. Acute toxicity (RTOG, CTC as well as patient-reported CTC, IPSS and ICIQ) during RT and 3 months after was mild to moderate with a tendency of recovery to baseline levels at 3 months post RT. No G3+ toxicity was scored for any item. Conclusions: In this first report on SRT of prostate cancer patients on a 1.5 T MRL, we could demonstrate the feasibility of both available workflows. Daily MR-guided adaptive SRT of mean 25.1 min per fraction was well tolerated in this pretreated collective, and we report low rates of acute toxicity for this treatment. This study suggests that SRT on a 1.5 T MRL can be performed in clinical routine and it serves as a benchmark for future analyses.